MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Organization & Developments: Reata
Parents
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Children
**Reata focuses on developing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation.
*Bardoxolone activates the Nrf2 gene, improving the filtration rate of the kidneys.
*But in the course of clinical trials, researchers noticed improved renal function in subjects who were given the drug, prompting Reata to shift its focus to chronic kidney disease and diabetes.
*Reata originally set out to develop bardoxolone as an oncology drug.
2017: Is It Time To Follow Insiders Into Reata Pharmaceuticals? - Reata Pharmaceuticals (NASDAQ:RETA)
2018: Can Reata Pharmaceuticals Continue To Rally? - Reata Pharmaceuticals (NASDAQ:RETA)
2018: Following Insiders Into This Attractive Small Cap Biotech - Bret Jensen
2018: Reata Pharmaceuticals Hits A Double With 2 Positive Mid-Stage Results For Chronic Kidney Disease_seekingalpha.com
2019: Reata Pharmaceuticals: Prospect In Pulmonary Arterial Hypertension - Reata Pharmaceuticals (NASDAQ:RETA)
2019: Reata: Blooming With Orphans_seekingalpha.com
2019: Reata’s Kidney Drug Hits Goals of Key Study, Paves Way for FDA Filing
2020: Reata Pharmaceuticals Can Rally
2021: FDA slams Reata's kidney drug as ineffective ahead of adcomm meeting
2021: Reata Pharmaceuticals: Finally, We Have A PDUFA
2021: Revisiting Reata Pharmaceuticals Again
2022: FDA rejects Reata's kidney drug after adcomm voted unanimously against it
2022: Why Reata Pharmaceuticals Could Perform Below Expectations_seekingalpha.com
2023: Reata Pharmaceuticals: Buy While Preparing For First Commercial Launch_seekingalpha.com
2023: Reata Pharmaceuticals: Still A Buy After Skyclarys Approval Jump_ seekingalpha.com
Jumps
*Key People: Reata
Finance & Acquisitions: Reata